Literature DB >> 31084761

Prognostic value of preoperative dynamic contrast-enhanced magnetic resonance imaging in epithelial ovarian cancer.

Auni Lindgren1, Maarit Anttila2, Otso Arponen3, Suvi Rautiainen4, Mervi Könönen5, Ritva Vanninen6, Hanna Sallinen7.   

Abstract

OBJECTIVES: To investigate whether semi-quantitative and pharmacokinetic perfusion dynamic contrast-enhanced (DCE) parameters are associated with traditional prognostic factors and can predict clinical outcome in ovarian cancer (OC).
METHODS: This prospective study, approved by local ethical committee, enrolled 38 patients with primary OC, 2011-2014. After preoperative DCE-MRI (3.0 T), two observers measured perfusion (Ktrans, Kep, Ve, Vp) and semi-quantitative parameters (area under the curve, peak, time-to-peak) by drawing regions of interest (ROIs) covering the large solid lesion (L-ROI) and the most enhancing small area (S-ROI) (NordicICE platform). Kruskal-Wallis was used to analyze associations between MRI parameters and classified prognostic factors.
RESULTS: Mean Ktrans values were higher in high-grade serous OC than in other types (L-ROI, P = 0.041; S-ROI, P = 0.018), and lower mean Ktrans values predicted residual tumor (L-ROI P = 0.030; S-ROI, P = 0.012). Higher minimum Vp values were associated with higher International Federation of Gynecology and Obstetrics (FIGO) stage (S-ROI, P = 0.023).Shorter recurrence-free survival was predicted by higher Ve (minimum L-ROI, P = 0.035; maximum S-ROI, P = 0.046), Vp (maximum S-ROI, P = 0.033), and lower time-to-peak (maximum S-ROI, P = 0.047) in Kaplan-Meier analysis. Multiparametric MRI variables combining DCE and diffusion weighted data were also predictive for survival.
CONCLUSION: DCE-MRI parameters may represent imaging biomarkers for predicting tumor aggressiveness and prognosis in OC. Higher Ktrans levels were associated with better results in cytoreductive surgery but with earlier recurrence.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Dynamic contrast-enhanced imaging; Magnetic resonance imaging; Ovarian cancer; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 31084761     DOI: 10.1016/j.ejrad.2019.03.023

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  The Value of Magnetic Resonance Diffusion-Weighted Imaging and Dynamic Contrast Enhancement in the Diagnosis and Prognosis of Treatment Response in Patients with Epithelial Serous Ovarian Cancer.

Authors:  Pawel Derlatka; Laretta Grabowska-Derlatka; Marta Halaburda-Rola; Wojciech Szeszkowski; Krzysztof Czajkowski
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 2.  Current update on malignant epithelial ovarian tumors.

Authors:  Sherif B Elsherif; Priya R Bhosale; Chandana Lall; Christine O Menias; Malak Itani; Kristina A Butler; Dhakshinamoorthy Ganeshan
Journal:  Abdom Radiol (NY)       Date:  2021-06-05

3.  Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1α expression.

Authors:  Auni Lindgren; Maarit Anttila; Suvi Rautiainen; Otso Arponen; Kirsi Hämäläinen; Mervi Könönen; Ritva Vanninen; Hanna Sallinen
Journal:  PLoS One       Date:  2019-08-22       Impact factor: 3.240

4.  MicroRNA-145-5p regulates the proliferation of epithelial ovarian cancer cells via targeting SMAD4.

Authors:  Jie Zhou; Xiyi Zhang; Weiling Li; Yuanyuan Chen
Journal:  J Ovarian Res       Date:  2020-05-04       Impact factor: 4.234

5.  Machine Learning Models and Multiparametric Magnetic Resonance Imaging for the Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Carmen Herrero Vicent; Xavier Tudela; Paula Moreno Ruiz; Víctor Pedralva; Ana Jiménez Pastor; Daniel Ahicart; Silvia Rubio Novella; Isabel Meneu; Ángela Montes Albuixech; Miguel Ángel Santamaria; María Fonfria; Almudena Fuster-Matanzo; Santiago Olmos Antón; Eduardo Martínez de Dueñas
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.